The efficacy and safety of direct-acting antiviral agents in patients with chronic HCV infection and UGT1A1*28 polymorphism

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(1):71-80

​ Lukashyk S.P., Karpov I.A., Siniauskaya M.G., Danilenko N.G., Anisko L.A., Davydenko O.G., Krasko O.V.
10.36488/cmac.2020.1.71-80
HCV infection UGT1A1\*28 direct-acting antiviral agents efficacy adverse events
Section
Personal Experience
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(1):71-80

Objective.

To determine the efficacy and safety of direct-acting antiviral agents (DAA) in patients with chronic HCV infection and UGT1A1*28 polymorphism.

Materials and Methods.

An open-label, non-randomized, observational study to assess efficacy and safety of DAA in patients (n = 143) with chronic hepatitis C (CHC) and liver cirrhosis and UGT1A1*28 polymorphism was performed. A total of 139 patients with chronic HCV infection were included in the efficacy analysis (absence of HCV RNA in blood by PCR) by the rate of sustained virologic response at week 12 (SVR12).

Results.

The SVR12 rate in patients with CHC and HCV-CP was 92.5% and 87.9%, respectively (p = 0.508), regardless of the presence of UGT1A1*28 polymorphism. The SVR12 rate in patients with chronic HCV infection and (TA)7/(TA)7 was 84.8%, with (TA)6/(TA)7 – 92.2% compared with (TA)6/ (TA)6 – 90,5% (p = 0.518). The rate of SVR12 in patients with CHC and (TA)7/(TA)7 or (TA)6/(TA)7 was 80% and 95%, respectively, with (TA)6/(TA)6 – 95.2%. The rate of SVR12 in patients with liver cirrhosis and (TA)7/(TA)7 or (TA)6/(TA)7 was 92.3% and 87.5%, respectively, with (TA)6/(TA)6 – 85.7%. The rate of SVR12 in patients with 12- and 24-week treatment duration was 88.2% and 96.6%, respectively (p = 0.30). As many as 96.2% of patients with the previous treatment with interferon and ribavirin had SVR12 compared to 88.5% of patients who have not previously taken antiviral drugs (p = 0.486). Grade 1 adverse events (AE) occurred in 24% of patients with chronic HCV infection treated with DAA; two patients developed Grade 4 AE.

Conclusions.

The treatment with DAA was shown to be effective and safe in patients with chronic HCV infection and UGT1A1*28 polymorphism.

Svyatlana P. Lukashyk

Belarusian State Medical University, Minsk, Belarus

Igor A. Karpov

Belarusian State Medical University, Minsk, Belarus

Siniauskaya M.G.

Institute of Genetics and Cytology, Minsk, Belarus

Danilenko N.G.

Institute of Genetics and Cytology, Minsk, Belarus

Anisko L.A.

Belarusian State Medical University, Minsk, Belarus

Davydenko O.G.

United Institute of Informatics Problems, Minsk, Belarus

Krasko O.V.

United Institute of Informatics Problems, Minsk, Belarus

  • 1. Petruzziello A., Loquercio G., Sabatino R., Vasile D., Najeeb B., Khan U., et al. Prevalence of Hepatitis C virus genotypes in nine selected European countries: A systematic review. J Clin Lab Anal. 2019;33(5):e22876. DOI: 10.1002/jcla.22876
  • 2. Hanafiah K.M., Groeger J., Flaxman A.D., Wiersma S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-1342. DOI: 10.1002/hep.26141
  • 3. Leroy V., Dumortier J., Coilly A., Sebagh M., Fougerou-Leurent C., Radenne S., et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis c after liver transplantation. Clin Gastroenterol Hepatol. 2015;13(11):1993-2001.e1-2. DOI: 10.1016/j.cgh.2015.05.030
  • 4. Reddy K.R., Bourlière M., Sulkowski M., Omata M., Zeuzem S., Feld J.J., et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology. 2015;62(1):79-86. DOI: 10.1002/hep.27826
  • 5. Saxena V., Koraishy F.M., Sise M.E., Lim J.K., Schmidt M., Chung R.T., et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36(6):807-816. DOI: 10.1111/liv.13102.
  • 6. Caudle K.E., Klein T.E., Hoffman J.M., Muller D.J., WhirlCarrillo M., Gong L., et al. Incorporation of pharmacogenomics into routine clinical practice: The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209-217. DOI: 10.2174/1389200215666140130124910
  • 7. Swen J.J., Nijenhuis M., de Boer A., Grandia L., Maitland-van der Zee A.H., Mulder H., Pharmacogenetics: From Bench to Byte – An Update of Guidelines. Clin Pharmacol Ther. 2011; 89(5):662-673. DOI: 10.1038/clpt.2011.34
  • 8. Torres A .К., Escartín N., Monzó C., Guzmán C., Ferrer I., González-Muñoz C. et al. Genetic susceptibility to Gilbert’s syndrome in a valencian population; efficacy of the fasting test. Rev Clin Esp. 2017;217(1):1-6. DOI: 10.1016/j.rce.2016.10.001
  • 9. Köhle C., Möhrle B., Münzel P.A., Schwab M., Wernet D., Badary O.A. Frequent co-occurrence of the TATA box mutation associated with Gilbert’s syndrome (UGT1A1\*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem. Pharmacol. 2003;65(9):1521-1527. DOI: 10.1016/s0006-2952(03)00074-1
  • 10. Balram C., Sabapathy K., Fei G., Khoo K.S., Lee E.J. Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1\*28 is a common allele in Indians. Pharmacogenetics. 2002;12(1):81-83. DOI: 10.1097/00008571-20020100000012
  • 11. Beutler E., Gelbart T., Demina A. Racial variability in the UDPglucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95(14):8170-8174. DOI: 10.1073/pnas.95.14.8170
  • 12. Ando Y., Chida M., Nakayama K., Saka H., Kamataki T. The UGT1A1\*28 allele is relatively rare in a Japanese population. Phar macogenetics.1998;8(4):357-360. DOI: 10.1097/00008571199808000-00010
  • 13. Bosma P.J., Chowdhury J.R., Bakker C., Gantla S., de Boer A., Oostra B.A., et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med. 1995;333(18):1171-1175. DOI: 10.1056/NEJM199511023331802
  • 14. Melnikova L.I., Ilchenko L.Yu., Dunaeva E.A., Kozitsyna M.V., Dribnokhodova O.P., Mironov K.O. Diagnosis of gilbert’s syndrome via pyrosequencing in clinical practice. Arhiv’’ vnutrennej mediciny. 2019;9(6):475-482. Russian. DOI: 10.20514/2226-6704-2019-9-6475-482
  • 15. Il'chenko L.J., Drozdov V.N., Shuljap'ev I.S., Petrakov A.V., Karabinov A.V. Sindrom Gilbert's syndrome: a clinical genetic study. Terapevticheskij arhiv. 2006;78(2):48-52. Russian.
  • 16. Nambu M., Namihisa T. Hepatic transport of serum bilirubin, bromsulfophthalein, and indocyanine green in patients with congenital non-hemolytic hyperbilirubinemia and patients with constitutional indocyanine green excretory defect. J Gastroenterol. 1996;31(2):228-236. DOI: 10.1007/bf02389522
  • 17. Martin J.F., Vierling J.M., Wolkoff A.W., Scharschmidt B.F., Vergalla J., Waggoner J.G., et al. Abnormal hepatic transport of indocyanine green in Gilbert’s syndrome. Gastroenterology. 1976;70(3):385-391.
  • 18. Ha V.H., Jupp J., Tsang R.Y. Oncology drug dosing in gilbert syndrome associated with ugt1a1: A summary of the literature. Pharmacotherapy. 2017;37(8):956-972. DOI: 10.1002/phar.1946
  • 19. Lankisch T.O., Vogel A., Eilermann S., Fiebeler A., Krone B., Barut A., et al. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol Pharmacol. 2005;67(5):1732-1739. DOI: 10.1124/mol.104.007146
  • 20. Kirby B.J., Symonds W.Т., Kearney B.P., Mathias A.A. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the Hepatitis C Virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54(7):677-690. DOI: 10.1007/s40262-015-0261-7
  • 21. Garimella T., You X., Wang R., Huang S.-P., Kandoussi H., Bifano M., et al. A review of daclatasvir drug-drug interaction. Adv Ther. 2016;33(11):1867-1884. DOI: 10.1007/s12325016-0407-5
  • 22. Mogalian E., Stamm L.M., Osinusi A., Brainard D.M., Shen G., Ling K.H., et al. Drug-drug interaction studies between hepatitis c virus antivirals sofosbuvir/velpatasvir and boosted and unboosted human immunodeficiency virus antiretroviral regimens in healthy volunteers. Clin Infect Dis. 2018;67(6):934-940. DOI: 10.1093/cid/ciy201.
  • 23. German P., Mathias A., Brainard D.M., Kearney B.P. Drug-drug interaction profile of the fixed-dose combination tablet regimen ledipasvir/sofosbuvir. Clin Pharmacokinet. 2018;57(11):13691383. DOI: 10.1007/s40262-018-0654-5
  • 24. Garrison K.L., German P., Mogalian E., Mathias A. The drug-drug interaction potential of antiviral agents for the treatment of chronic Hepatitis C infection. Drug Metab Dispos. 2018;46(8):12121225. DOI: 10.1124/dmd.117.079038
  • 25. Stroup W.W. Generalized Linear Mixed Models: Modern Concepts, Methods and Applications. CRC Press; 2012. 547 р.
  • 26. Jiang J. Linear and Generalized Linear Mixed Models and Their Applications. Springer Science & Business Media. 2007. 257 р.
  • 27. Konietschke F., Brunner E., Hothorn L.A. Nonparametric Relative Contrast Effects: Asymptotic Theory and Small Sample Approximations; 2008. Available at: https://rdrr.io/cran/nparcomp/man/nparcomp.html.
  • 28. Agresti A. Categorical Data Analysis. 2nd Edition, John Wiley & Sons, Inc., New York. 2002, 320-332. Available at: http://dx.DOI.org/10.1002/0471249688 DOI: 10.1002/0471249688
  • 29. Jonckheere A.R. A distribution-free k-sample test again ordered alternatives. Biometrika. 1954;41:133-145. DOI: 10.2307/2333011
  • 30. Terpstra T.J. The asymptotic normality and consistency of Kendall's test against trend, when ties are present in one ranking. Indagationes Mathematicae. 1952;14:327-333.
  • 31. R Core Team. The R Project for Statistical Computing. Available at: www.r-project.org/. Accessed 09.02.2020.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared